title: Infusional chemotherapy and medication errors in a tertiary care pediatric cancer unit in a resource-limited setting.
abstract: BACKGROUND
  Drug administration is a multiprofessional process. The high toxicity and low therapeutic index of chemotherapy drugs make medication errors a significant problem, resulting in excessive patient morbidity and cost.
  
  
  OBJECTIVE
  An audit of the delivery of infusional chemotherapy among pediatric inpatients was planned, with the objective of improving practice and minimizing errors.
  
  
  METHODS
  An observational study was conducted between January and August 2012. Patients were followed up from their premedication until the completion of postchemotherapy hydration and/or rescue drugs. Errors were recorded and classified by error type, cause, severity, unit location, medication involved, and harm caused.
  
  
  RESULTS
  A total of 205 observations were made and 23(13.6%) errors recorded, of which 6 were intercepted. No life-threatening adverse drug event was recorded. The most important risk factor predisposing to errors was admission to nonpediatric ward (P=0.004). Documentation errors and incorrect infusion time were the 2 most common errors, whereas the most frequent error node was administration error. Appropriate steps were taken to prevent their reoccurrence.
  
  
  CONCLUSIONS
  This study helped provide important information about the rate and epidemiology of medication errors, emphasizing on the role of audit in enabling development of appropriate error-reducing strategies, particularly in the context of quality assurance in hospitals.
authors.affiliation: *Department of Pediatric Hematology and Oncology, Rajiv Gandhi Cancer Institute and Research Centre †National Institute of Medical Statistics, New Delhi, India.
authors.forename: Mayank
authors.initials: M
authors.lastname: Dhamija
authors.forename: Gauri
authors.initials: G
authors.lastname: Kapoor
authors.forename: Atul
authors.initials: A
authors.lastname: Juneja
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D002648:Child; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007194:India / Q000453:epidemiology; D007262:Infusions, Intravenous; D007902:Length of Stay / Q000706:statistics & numerical data; D008297:Male; D008485:Medical Audit; D008508:Medication Errors / Q000706:statistics & numerical data*; D009017:Morbidity; D009369:Neoplasms / Q000188:drug therapy / Q000453:epidemiology; D016522:Oncology Service, Hospital / Q000592:standards / Q000706:statistics & numerical data*; D011785:Quality Assurance, Health Care; D012307:Risk Factors; D012308:Risk Management / Q000592:standards / Q000706:statistics & numerical data; D062606:Tertiary Care Centers / Q000592:standards / Q000706:statistics & numerical data*
chemical_list: D000970:Antineoplastic Agents